Goldman Sachs raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $3 from $2 and keeps a Sell rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Midday Fly By: Paramount wins Warner bidding, Amazon to invest $5oB in OpenAI
- Rocket Pharmaceuticals price target raised to $10 from $8 at Cantor Fitzgerald
- Rocket Pharmaceuticals: Advancing Gene Therapy Pipeline and High-Confidence KRESLADI Approval Drive Buy Rating
- Balanced View on RCKT: Clinical Progress Offsetting Execution and Regulatory Risks Supports Hold Rating
- Rocket Pharmaceuticals reports Q4 EPS (38c), consensus (42c)